A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
Recruiting now · Not applicable
Conditions studied: Endometrial Cancer
In brief
The researchers are doing this study to see how well multiparametric ultrasound (mpUS) imaging can evaluate vaginal tissue before and after IVRT. IVRT is routinely used to treat endometrial cancer but can cause damage to the vaginal tissue (vaginal toxicity). Side effects of vaginal toxicity can include vaginal dryness, itching, soreness, discharge, narrowing or shortening of the vagina (stenosis), and vaginal fibrosis (hardening), which can affect sexual function. The researchers will also look at whether participants are able to complete (tolerate) all mpUS imaging for this study.
Key facts
- Study ID
- NCT07318415
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 10
- Starts
- 2025-12-11
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-01-06
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Patients must be diagnosed with a primary endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serious, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma
- Initial surgical treatment must have included hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node assessment with either sentinel lymph node mapping/sampling or pelvic lymph node dissection. Surgical assessment of the para-aortic lymph nodes is not required
- Patients must have had a complete surgical resection with negative margins and no residual gross disease after surgery
- Patients must have FIGO (2009) stage I-II disease (per surgical staging)
- Age ≥ 18 years
- Patients must be able to start radiotherapy within 12 weeks from date of surgery
You may not qualify if…
- Patients receiving chemotherapy or hormonal therapy
- A prior or concurrent malignancy whose natural history or treatment would interfere with the toxicity or efficacy assessment of IVRT
- Prior pelvic radiotherapy
- Active genitourinary infection requiring antibiotics, except for uncomplicated urinary tract infection
- History of active inflammatory bowel disease requiring treatment, including Crohn's disease and ulcerative colitis
- Concurrent psychiatric or medical condition or disease which, per investigator judgement, would make them unsuitable candidates for study enrollment
Where it is running
- Memorial Sloan Kettering at Basking Ridge (Consent Only) — Basking Ridge, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Monmouth (Consent Only) — Middletown, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Suffolk - Commack (Consent Only) — Commack, New York, United States (enrolling)
- Memorial Sloan Kettering Westchester (Consent Only) — Harrison, New York, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- Memorial Sloan Kettering Nassau (Consent Only) — Uniondale, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.